Tnm Staging Calculator

TNM describes the anatomic extent of a solid tumor along three independent axes. T grades the primary lesion from Tis (carcinoma in situ, malignant cells that have not breached the basement membrane) through T1 to T4, using size at some sites and depth of invasion at others: breast cancer separates T1, T2 and T3 at the 2 cm and 5 cm marks, while colorectal T1 to T4 track penetration through submucosa, muscularis propria, pericolorectal fat and finally the visceral peritoneum or an adjacent organ. N grades regional nodal burden from N0 to N3 within the drainage basin belonging to that organ; in breast cancer N1 is 1 to 3 positive axillary nodes, N2 is 4 to 9, and N3 is 10 or more. M is binary, and any M1 forces the overall group to Stage IV however small T and N happen to be. Stage groups 0 through IV exist because they were fitted to survival data so that each successive group separates outcomes. Prefixes record the evidence source: c for clinical staging from examination and imaging, p for pathologic staging from the resection specimen, yp after neoadjuvant treatment, and r for recurrence. The generic rules applied here are a teaching approximation; real staging requires the site-specific chapter of the AJCC manual, and the 8th edition folded non-anatomic factors such as grade and ER, PR and HER2 status into breast stage groups. Node yield also matters mechanically, since examining fewer than the recommended 12 nodes in a colon resection understages patients, a form of stage migration that distorts comparisons across eras.

The system originated with Pierre Denoix, a surgeon at the Institut Gustave-Roussy near Paris, who set out the tumor-node-metastasis idea in a series of papers published between 1943 and 1952. His argument was that the three components of spread, local growth, lymphatic spread and bloodborne spread, progress semi-independently and should be recorded separately rather than collapsed into a single impression of severity. The Union for International Cancer Control took up the scheme, forming a committee on clinical stage classification in 1950 and issuing site-by-site brochures through that decade before collecting them into the first TNM Classification of Malignant Tumours in 1968. In the United States the American Joint Committee for Cancer Staging and End Results Reporting was founded in 1959 and published its first staging manual in 1977, initially with definitions that diverged from the UICC in places. The two bodies harmonized their criteria in 1987, so that a designation such as T3N1M0 carries the same meaning on both sides of the Atlantic. New editions have appeared every several years since, each rebuilt from pooled outcome databases rather than expert opinion alone. The 8th edition, published in 2016 and put into routine practice from 1 January 2018 after a delay for data validation, was the first to admit biological rather than purely anatomic variables into stage grouping.